Skip to main
RNA
RNA logo

Avidity Biosciences (RNA) Stock Forecast & Price Target

Avidity Biosciences (RNA) Analyst Ratings

Based on 22 analyst ratings
Buy
Strong Buy 41%
Buy 55%
Hold 5%
Sell 0%
Strong Sell 0%

Bulls say

Avidity Biosciences Inc. has demonstrated significant advancements in its pipeline, particularly with its DM1, FSHD, and DMD programs, as evidenced by the recent clinical trial results showing a notable improvement in exon skipping and dystrophin production. The latest data from the 10 mg/kg cohort revealed a statistically significant 43% improvement in exon skipping and a nearly 30% normalization of dystrophin production levels, which bodes well for continued efficacy and safety in patients. These findings, alongside consistent improvements across key biomarkers and a favorable safety profile, bolster the optimistic outlook for Avidity Biosciences' future growth and market potential in the RNA therapeutic landscape.

Bears say

Avidity Biosciences Inc's financial outlook is negatively affected by the inherent risks associated with its clinical programs, as the outcomes of ongoing phase I/II/III trials are uncertain and could lead to significant share volatility based on their success or failure. Additionally, the potential emergence of new treatment methods for the diseases the company targets could undermine the competitiveness of its RNA therapeutics, further complicating its market position. Furthermore, weaknesses in intellectual property protection and the possibility of costly legal battles due to infringement could impose additional financial strain on the company.

Avidity Biosciences (RNA) has been analyzed by 22 analysts, with a consensus rating of Buy. 41% of analysts recommend a Strong Buy, 55% recommend Buy, 5% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Avidity Biosciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Avidity Biosciences (RNA) Forecast

Analysts have given Avidity Biosciences (RNA) a Buy based on their latest research and market trends.

According to 22 analysts, Avidity Biosciences (RNA) has a Buy consensus rating as of Jul 3, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $54.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $54.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Avidity Biosciences (RNA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.